Comparison of Frequency of Radial Artery Occlusion After 4Fr Versus 6Fr Transradial Coronary Intervention (from the Novel Angioplasty USIng Coronary Accessor Trial)

详细信息    查看全文

• 作者：Satoshi Takeshita ; MD^a ; ^{stake@muse.ocn.ne.jp" class="auth_mail} ; Hiroshi Asano ; MD^b ; Tetsuya Hata ; MD^c ; Kiyoshi Hibi ; MD^d ; Yuji Ikari ; MD^e ; Yoshifumi Kan ; MD^f ; Takaaki Katsuki ; MD^g ; Tomohiro Kawasaki ; MD^h ; Motomaru Masutani ; MDⁱ ; Toshiyuki Matsumura ; MD^j ; Rajendra K. Premchand ; MD^k ; Surya P. Rao ; MD^l ; Takashi Suzuki ; MD^m ; Akihiko Takahashi ; MDⁿ ; Ryuichi Takeda ; MD^o ; Shinji Tanaka ; MD^p ; Seiji Yamazaki ; MD^q ; Wei-Hsian Yin ; MD^r ; Fuminobu Yoshimachi ; MD^s ; Shigeru Saito ; MD^t ; on behalf of the NAUSICA Trial Investigators
• 刊名：The American Journal of Cardiology
• 出版年：15 June 2014
• 年：2014
• 卷：113
• 期：12
• 页码：1986-1989
• 全文大小：100 K

文摘

The frequency of radial artery occlusion was compared between patients receiving 4Fr versus 6Fr transradial coronary interventions (TRIs) in an open-label randomized trial (ClinicalTrials.gov identifier: NCT00815997). The primary outcome measure was radial artery occlusion on the day after TRI. The secondary outcome measures were the procedural success, major advanced cardiac events, access site–related complications, procedural times, fluoroscopy times, and contrast dye usage. A total of 160 patients were included. The procedure was successful in 79 of 80 patients (99%) in both groups. Whereas the 4Fr group showed no access site–related complications, the 6Fr developed 5 (6%), including 3 radial artery occlusions and 2 bleedings (1 radial artery perforation and 1 massive hematoma; p = 0.02). Although the radial artery occlusion rate was lower in the 4Fr versus the 6Fr groups, the difference was not significant (0% vs 4%, p = 0.08). The mean hemostasis time was significantly shorter in the 4Fr than in the 6Fr groups (237 ± 105 vs 320 ± 238 minutes, p = 0.007). In conclusion, these findings suggest that 4Fr TRI may become a less invasive alternative to 6Fr TRI in treating coronary artery diseases.